[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_3393",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_3393"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00315"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "\"Zolmitriptan is contraindicated in patients with:   Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or  c Warnings and Precautions ( 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see  Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see  Warnings and Precautions ( 5.4 Peripheral vascular disease (PVD) [see  Warnings and Precautions ( 5.5 Ischemic bowel disease [see  Warnings and Precautions ( 5.5 Uncontrolled hypertension [see  Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see  Drug Interactions ( 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see  Drug Interactions ( 7.2 Clinical Pharmacology ( 12.3 Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see  Adverse Reactions ( 6.2   History of coronary artery disease (CAD) or coronary vasospasm ( 4 Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 Monamine oxidase (MAO)-A inhibitor used in past 2 weeks ( 4 Known hypersensitivity to zolmitriptan ( 4\""
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/MedicalContraindication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00315",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-23T18:00:23.548+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "UFwMfnbaGsXMkKmJYORpF/4E3FM7g3KhP0yfjN0fKHKIV9GFuTXvLVRHgYEH1Yq0OYpIpgZjfYj0FkXU00esIvAETt0rGwEMQSbF10Tyn3wib73rmbaBBgmsn+KRJ3f6WReLN/Npt7VCmSII64VkrwrF7SUIXvHATMHo0rR4AlU="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo"
} ]